Most people are familiar with A, B, AB and O blood types, but there are hundreds of additional blood group “antigens” on red blood cells – substances that can trigger the body’s immune response – that differ from person to person. Each year, up to 16 deaths reported to the Federal Drug Administration are attributed to mismatches in red blood cell antigens that are not related to differences in A, B and O blood groups. Currently, no method is available that can determine all blood antigens. But as whole genome sequencing becomes routine for patients, it may be possible to modernize therapy by identifying both rare donors and at-risk recipients before blood transfusions.
In a new study, investigators from Brigham and Women’s Hospital and Harvard Medical School, as well as from the New York Blood Center have leveraged the MedSeq Project – the first randomized trial of whole genome sequencing in healthy adults – to develop and validate a computer program that can comprehensively and cost-effectively determine differences in individuals’ blood types with more than 99 percent accuracy. The team’s results are reported in The Lancet Haematology.
“Blood transfusion complications are common in patients needing chronic transfusion, but with current technology it is not cost effective to do blood typing for all antigens,” said first author William Lane, MD, PhD, director of Clinical Laboratory Informatics and assistant director of the Tissue Typing Laboratory in the BWH Department of Pathology. “But the algorithm we have developed can be applied to type everyone for all relevant blood groups at a low cost once sequencing is obtained.”
Blood transfusions are one of the most common procedures in medicine with more than 11 million units of blood transfused in the U.S. each year. Complications from blood transfusions can be life-threatening. When the body encounters foreign antigens on the donor cells, it can stimulate production of antibodies that can destroy the transfused donor cells. From birth, people have antibodies unique to their ABO blood type, but other antibodies against specific blood antigens can be stimulated during pregnancy from exposure to fetal cells or exposure to donor cells when receiving multiple blood transfusions.
“This approach has the potential to be one of the first routine clinical uses of genomics for medical care for patients needing blood transfusion,” said co-first author Connie M. Westhoff, PhD, at the New York Blood Center. “It could prevent serious or even fatal complications because once patients are sensitized they have a life-long risk of hemolytic transfusion reactions if blood transfusion is needed in an emergency.”
Today, most testing for blood donors and patients include only ABO and Rh matching, but more than 300 red blood cell antigens and 33 platelet antigens are known. To create a way to cost-effectively type many people for these antigens, Lane teamed up with scientists directing the MedSeq Project and experts in blood group genetics at the New York Blood Center to build a database and develop a computer software algorithm, known as bloodTyper, that could rapidly and accurately predict an individual’s blood group antigen profile from genomic sequences. Lane, Westhoff and colleagues validated the software by comparing it to traditional, and more labor-intensive, methods. bloodTyper was more than 99 percent accurate when typing from the MedSeq Project participants’ genomes. Lane notes that this work would not have been possible without access to samples from the MedSeq Project, and close collaboration with MedSeq’s principal investigator, Robert Green, MD, MPH, and co-investigator, Heidi Rehm, PhD.
“This report demonstrates a previously unanticipated use case and benefit that will accrue as whole genome sequencing become a routine part of medical care,” said Green, one of the senior authors on the study, director of the Genomes2People Research Program at BWH and professor of medicine at Harvard Medical School. “Genome sequencing can now identify potential transfusion recipients who need rare blood types and the individuals who can safely provide them.”
The Latest on: Whole genome sequencing
via Google News
The Latest on: Whole genome sequencing
- San Diego biotech company teams up with doctors to offer genome sequencing to Tijuana children on February 19, 2019 at 6:29 pm
Now through an alliance with the San Diego biotech company Illumina, Jones has a powerful new tool as she works with young Mexican patients and their families: a diagnostic test known as whole genome ... […]
- Ultrasensitive DNA Screening for Down Syndrome Offers Potential for Early Detection on February 18, 2019 at 9:04 am
Through PCR (polymerization chain reaction) amplification of the fetal DNA in the pregnant mother’s peripheral blood and fluorescence read-out, whole-genome sequencing (WGS)-based non-invasive prenata... […]
- Ten European Genomics Companies to Watch Out For on February 18, 2019 at 7:53 am
Given the range of companies out there, selecting ten was hardly straightforward, and we decided to focus on those sequencing or dealing with whole genome data. In no particular order, this is our sho... […]
- Whole Genome Sequence, Variant Discovery and Annotation in Mapuche-Huilliche Native South Americans on February 14, 2019 at 2:27 am
Whole human genome sequencing initiatives help us understand population history and the basis of genetic diseases. Current data mostly focuses on Old World populations, and the information of the geno... […]
- Whole-genome sequencing and sharing real-time data could limit spread of foodborne bacteria on February 13, 2019 at 11:05 pm
Employing advanced genetic-tracing techniques and sharing the data produced in real time could limit the spread of bacteria -- Bacillus cereus-- which cause foodborne illness, according to researchers ... […]
- Cancer Genome Sequencing Market Growth Focusing on Trends & Innovations During the Period Until 2023 on February 13, 2019 at 3:47 pm
Factors supporting cancer genome sequencing encompass comprehensive view of whole genome, ability to majority of mutations, and eliminating the need for having any knowledge beforehand about the patie... […]
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing on February 13, 2019 at 4:14 am
Cancer Therapy Advisor (CTA): What is the difference between whole-exome sequencing (WES) and whole-genome sequencing (WGS)? Dr Gerstein: WGS sequences a patient's entire genome. You get the DNA and s... […]
- Why whole genome sequencing is important for food safety on February 12, 2019 at 2:23 pm
In 1999, I gave a talk to hundreds of farm leaders in Ottawa and told them that DNA fingerprinting – via PulseNet – would revolutionize foodborne illness outbreak investigations and that farmers bette... […]
- Next Generation Sequencing (NGS) Market Innovations, Trends, Technology And Applications Market Report to 2019-2026 on February 12, 2019 at 2:18 am
By Technology, the global next generation sequencing market is further sub segmented into Whole Genome Sequencing, Targeted Re-Sequencing, Whole Exome Sequencing, RNA Sequencing, Chip Sequencing, De N... […]
via Bing News